Klara Owen becomes CMO at DiogenX

French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer.

DiogenX noted that Dr Owen brings a wealth of experience in the field of diabetes and metabolic disorders from both clinical and corporate perspectives. Notably, she has spent the last decade in senior positions in leading international pharmaceutical and biotech companies. She joins DiogenX from Novo Nordisk (NOV: N), where she was senior international medical director of cell therapy R&D. Before that, she spent almost four years as medical director at Zealand Pharma. Prior to this, she was also at Novo Nordisk, spending five years as international medical Director in various indications for insulins and incretins, from FHD to Phase IIIb. During her career, she led complex projects from rare pediatric diseases to multi-track T1D, which involved clinical trial design, leadership of clinical development teams, and shaping research and regulatory processes.

“I am delighted to welcome Dr Owen to DiogenX. Her experience in T1D and metabolic diseases in general, from clinical translation to Phase III, will be fundamental for the development of DGX-01, our lead candidate, through the clinical and regulatory processes,” said Benjamin Charles, chief executive of DiogenX.